Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CRISPR Therapeutics AG (CRSP : NSDQ)

• Company Description    CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases. Number of Employees: 473

• Price / Volume Information    Yesterday's Closing Price: $56.34 Daily Weekly Monthly 20 Day Moving Average: 1,486,675 shares Shares Outstanding: 77.46 (millions) Market Capitalization: $4,363.93 (millions) Beta: 2.05 52 Week High: $169.76 52 Week Low: $42.51 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.46% 14.26% 12 Week -1.43% 8.35% Year To Date -25.65% -8.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL BAARERSTRASSE 14 - ZUG,V8 CH-6300 CHE ph: 41-41-561-3277 fax: - susan.kim@crisprtx.com http://www.crisprtx.com

• General Corporate Information    Officers Samarth Kulkarni - Chief Executive Officer Rodger Novak - President Brendan Smith - Chief Financial Officer Ali Behbahani - Director Bradley Bolzon - Director Peer Information CRISPR Therapeutics AG (CORR.) CRISPR Therapeutics AG (RSPI) CRISPR Therapeutics AG (CGXP) CRISPR Therapeutics AG (BGEN) CRISPR Therapeutics AG (GTBP) CRISPR Therapeutics AG (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: H17182108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 77.46 Most Recent Split Date: (:1) Beta: 2.05 Market Capitalization: $4,363.93 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-8.97 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 12.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 15.61 PEG Ratio: - Price Ratios Price/Book: 1.94 Price/Cash Flow: 10.52 Price / Sales: 4.77 EPS Growth vs. Year Ago Period: -53.64% vs. Previous Quarter: -26.09% Sales Growth vs. Year Ago Period: 74.40% vs. Previous Quarter: -92.71% ROE 03/31/22 - 12.77 12/31/21 - 16.21 09/30/21 - 19.19 ROA 03/31/22 - 11.25 12/31/21 - 14.48 09/30/21 - 17.33 Current Ratio 03/31/22 - 19.88 12/31/21 - 20.17 09/30/21 - 26.18 Quick Ratio 03/31/22 - 19.88 12/31/21 - 20.17 09/30/21 - 26.18 Operating Margin 03/31/22 - 34.04 12/31/21 - 41.28 09/30/21 - 45.64 Net Margin 03/31/22 - 34.04 12/31/21 - 41.28 09/30/21 - 45.64 Pre-Tax Margin 03/31/22 - 34.58 12/31/21 - 41.48 09/30/21 - 46.08 Book Value 03/31/22 - 28.98 12/31/21 - 31.35 09/30/21 - 32.98 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©